ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices, has been acquired by QGEN.
"We are excited about the addition of ESE's capabilities and technology portfolio. We believe it will considerably strengthen QIAGEN's portfolio of detection technologies and help us to better address the needs of our existing customers in a range of application fields. In addition, due to the unique features of ESE's technology, this transaction allows QIAGEN to synergistically apply our sample and assay technologies to the exciting, emerging point-of-need testing market segment," said Peer Schatz, QIAGEN's CEO. "QIAGEN has always been driving the dissemination of molecular biology. With this new technology portfolio, we now have the opportunity to shape a new dimension for molecular testing," Mr Schatz continued.
"The deal is a great fit for us," said Klaus Haberstroh, founder and CEO of ESE GmbH. "With its leadership in molecular sample and assay technologies, QIAGEN is the ideal partner to capitalize on our development and engineering know-how and to take our technology to the next level."
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,400 people in over 30 locations worldwide.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
